{"name":"Giovanni Di Perri","slug":"giovanni-di-perri","ticker":"","exchange":"","domain":"","description":"Giovanni Di Perri is a specialty pharmaceutical company focused on the development and commercialization of antiretroviral therapies for HIV. The company has a portfolio of three marketed drugs, including combination therapies that address unmet needs in the treatment of HIV.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"raltegravir and atazanavir and ritonavir","genericName":"raltegravir and atazanavir and ritonavir","slug":"raltegravir-and-atazanavir-and-ritonavir","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients","status":"marketed"},{"name":"emtricitabine, darunavir/cobicistat, maraviroc","genericName":"emtricitabine, darunavir/cobicistat, maraviroc","slug":"emtricitabine-darunavir-cobicistat-maraviroc","indication":"HIV-1 infection in treatment-experienced patients with CCR5-tropic virus","status":"marketed"}]}],"pipeline":[{"name":"raltegravir and atazanavir and ritonavir","genericName":"raltegravir and atazanavir and ritonavir","slug":"raltegravir-and-atazanavir-and-ritonavir","phase":"marketed","mechanism":"This is a three-drug antiretroviral combination that inhibits HIV replication through complementary mechanisms: raltegravir blocks HIV integrase, while atazanavir and ritonavir inhibit HIV protease.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients"],"catalyst":""},{"name":"emtricitabine, darunavir/cobicistat, maraviroc","genericName":"emtricitabine, darunavir/cobicistat, maraviroc","slug":"emtricitabine-darunavir-cobicistat-maraviroc","phase":"marketed","mechanism":"This is a three-drug combination that inhibits HIV replication through multiple mechanisms: emtricitabine and darunavir block reverse transcriptase and protease respectively, cobicistat enhances darunavir levels, and maraviroc blocks the CCR5 co-receptor.","indications":["HIV-1 infection in treatment-experienced patients with CCR5-tropic virus"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNa1RZS1BuSVhMbVZyTWhrLVltRDNiLUI2RHdOMEtBU282WVdGQ2Zld3QzQ0ZYWHREMzE3eEczSFVWeTNuRFptVEtYdFNuNmIzN0twTnQ0S291ei1SQXpFTklzZE14S0xHUzg4eV92cUc0el9DSV9sWjkwbjYybm10RDFzUFFIMW9QNzlWMHRPZFR3Nk15Q0JCTUd6RXF3QWNvM1BJb3BB?oc=5","date":"2018-03-31","type":"pipeline","source":"ScienceDirect.com","summary":"Journal of Pharmaceutical and Biomedical Analysis - ScienceDirect.com","headline":"Journal of Pharmaceutical and Biomedical Analysis","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}